# US 2008/0188547 A1 · Uses of ion channel modulating compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188547 A1
- Document ID: US20080188547A1
- Status: Published application
- Kind: A1
- Application number: 11/947,679
- Filed: 2007-11-29
- Published: 2008-08-07
- Earliest claimed: 2003-05-02
- Assignees: Cardiome Pharma Corp.
- Inventors: Gregory N. Beatch; Alan M. Ezrin
- Web page: https://patentgrep.com/patent/US20080188547A1

## CPC

- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 9/06: Antiarrhythmics
- C07D 207/12: Oxygen or sulfur atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.

## Claims

### Claim at position 1

1-112. (canceled)

### Claim 113

A method for preventing or postponing onset of arrhythmia in a human subject, the method comprising administering to the subject one or more doses of a formulation, wherein each dose of the formulation independently comprises an ion channel modulating compound of formula
including isolated enantiomeric, diastereomeric and geometric isomers thereof and mixtures thereof, or a solvate or pharmaceutically acceptable salt thereof;
wherein R4 and R5 are independently selected from hydrogen, hydroxy and C1-C6alkoxy; and
wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject has a mean trough concentration of greater than about 1 ng/ml and/or a steady state concentration of greater than about 1 ng/ml.

### Claim 114 (depends on 113)

The method of claim 113, wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject has a mean trough concentration of less than about 10 μg/ml and/or a steady state concentration of less than about 10 μg/ml.

### Claim 115 (depends on 113)

The method of claim 113, wherein the total concentration of the ion channel modulating compound in the blood plasma of the subject has a mean trough concentration of between about 0.3 μg/ml and about 3 μg/ml, and/or a steady state concentration between about 0.3 μg/ml and about 3 μg/ml.

### Claim 116 (depends on 113)

The method of claim 113, wherein the ion channel modulating compound is administered in two or more doses.

### Claim 117 (depends on 113)

The method of claim 113, wherein the doses are administered orally.

### Claim 118 (depends on 117)

The method of claim 117, wherein the formulation is a solid or liquid dosage form of the ion channel modulating compound.

### Claim 119 (depends on 113)

The method of claim 113, wherein the dose or doses are administered intravenously.

### Claim 120 (depends on 119)

The method of claim 119, wherein the formulation is an isotonic intravenous solution of the ion channel modulating compound.

### Claim 121 (depends on 113)

The method of claim 113, wherein each dose of the formulation comprises a monohydrochloride salt of the formula

### Claim 122 (depends on 113)

The method of claim 113, wherein the arrhythmia is an atrial arrhythmia.

### Claim 123 (depends on 122)

The method of claim 122, wherein the arrhythmia is an atrial fibrillation.
